The US Food and Drug Administration packed full of instructions a draft guidance on format and content for OTC monograph order requests (OMORs) but still made room to includes requests for more information than firms likely are accustomed to providing for monograph drugs.
“The extent of the data and information details recommended by FDA shows that many OMORs will involve a highly complex submission and review process, and may bear a similarity to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?